Aptamer Patents

DNA/RNA aptamer patents cover SELEX/aptamer-selection innovations; aptamer-composition innovations; biosensor/diagnostic innovations; and proteomics and stability/modification innovations — with IP held by aptamer/proteomics companies and the academic inventors of SELEX (in a field using synthetic nucleic-acid 'antibodies' for diagnostics and proteomics). WHY APTAMERS: APTAMERS are short, synthetic DNA/RNA (or peptide) molecules that FOLD into specific 3D shapes that BIND a target (protein, small molecule, cell) with high affinity and specificity — functioning like 'chemical/synthetic ANTIBODIES'; but unlike antibodies, aptamers are made by CHEMICAL synthesis (cheap, highly reproducible batch-to-batch, very stable, no animals/cells needed), are easily ENGINEERED/modified, and can bind targets antibodies struggle with — making them attractive molecular-recognition tools for DIAGNOSTICS, large-scale PROTEOMICS (measuring thousands of proteins at once), biosensors, and some therapeutics. MAJOR HOLDERS: SOMALOGIC (SomaScan — large-scale proteomics using modified aptamers/SOMAmers), APTAMER GROUP, BASE PAIR BIOTECHNOLOGIES, plus academic IP (the SELEX inventors). SELEX/aptamer selection, aptamer compositions, biosensors/diagnostics, proteomics, and stability/modification are the core aptamer patent domains — and selection methods, specific aptamers, diagnostics, and proteomics are the open whitespace.

SELEX/aptamer-selection innovations; aptamer-composition innovations; stability/modification innovations; and library/screening innovations represent core aptamer patent domains — and the selection process and the specific engineered aptamers are the foundational, high-value capabilities. SELEX / APTAMER-SELECTION PATENTS: the discovery ENGINE — SELEX (Systematic Evolution of Ligands by EXponential enrichment): an iterative IN-VITRO 'evolution' process that starts with a huge random library of nucleic acids and repeatedly SELECTS and amplifies those binding a target, enriching to high-affinity APTAMERS over rounds; SELEX variants/improvements (faster, higher-affinity, automated, against difficult targets, cell-SELEX) are core, high-value IP (the selection method is the engine — foundational SELEX is older/public, so improvements are the whitespace). APTAMER-COMPOSITION PATENTS: the specific aptamer SEQUENCE that binds a particular target (its sequence/structure) — composition IP for each aptamer-target pair; aptamer compositions are core, high-value IP (the specific aptamer is the product — and a synthetic molecule, more clearly patent-eligible than a natural one). STABILITY / MODIFICATION PATENTS: chemical MODIFICATIONS to the nucleic acid that improve performance — nuclease RESISTANCE (unmodified RNA/DNA degrades fast), higher AFFINITY, and (for therapeutics) half-life — including SomaLogic's modified nucleotides (SOMAmers) that add protein-like chemical groups to bind proteins better/more broadly; modification methods are high-value, distinctive IP (modifications are what make aptamers robust and broadly useful — SomaLogic's modified aptamers expanded the bindable proteome). LIBRARY / SCREENING PATENTS: library design and high-throughput screening; library methods are valuable. SELEX/selection improvements, aptamer compositions, and stability/modifications are the highest-value core IP because the selection engine and the specific, modified, stable aptamers are exactly what define aptamer technology.

Biosensor/diagnostic innovations; proteomics/multiplexed-measurement innovations; §101-navigating innovations; and therapeutic and assay-integration innovations represent additional aptamer patent domains — and using aptamers in tests, measuring thousands of proteins, and drafting eligible claims are where application value and defensibility concentrate. BIOSENSOR / DIAGNOSTIC PATENTS: using aptamers as the molecular RECOGNITION element in diagnostic tests and BIOSENSORS — aptamer-based assays, lateral-flow, electrochemical aptasensors, and point-of-care formats (aptamers can be EASIER to integrate than antibodies — chemically attachable, stable, signal-generating 'aptamer beacons'); biosensor/diagnostic methods are high-value IP (aptamer diagnostics leverage their synthesis/stability advantages). PROTEOMICS / MULTIPLEXED-MEASUREMENT PATENTS: large-scale, MULTIPLEXED protein measurement — using PANELS of thousands of aptamers to measure thousands of proteins in a sample at once (SomaLogic's SomaScan measures ~7,000+ proteins) for biomarker discovery, disease signatures, and research/clinical proteomics; proteomics-platform methods (panel design, readout, normalization) are high-value, distinctive IP (large-scale aptamer proteomics is SomaLogic's signature platform — a major application). §101-NAVIGATING PATENTS: aptamer DIAGNOSTICS detect natural targets/proteins (and may correlate with disease), risking §101 (Mayo natural-correlation) — but the engineered APTAMER itself is a synthetic, man-made molecule (clearly patent-eligible, like other synthetic molecules), and the assay is a concrete technical method; claiming the engineered aptamer and the specific technical assay/method (not the bare natural correlation) is §101-robust; §101-aware claiming is valuable. THERAPEUTIC / ASSAY-INTEGRATION PATENTS: aptamer THERAPEUTICS (aptamers as drugs — e.g., binding/blocking a target), and integrating aptamers into assay/sensor platforms; therapeutic and integration methods are valuable. Biosensors/diagnostics, proteomics, §101-robust claiming, and therapeutics are the highest-value application IP because aptamer-based tests, large-scale proteomics, enforceable claims, and therapeutics are exactly what turn aptamer technology into products.

Aptamer startup IP strategy must navigate SomaLogic's strong proteomics/modified-aptamer portfolio and academic SELEX IP (foundational SELEX is older/largely public — improvements and specific aptamers are the novelty), the antibody-competition reality (aptamers must beat established antibodies on cost/stability/reproducibility/target-coverage — and antibodies are entrenched, so aptamers win on specific advantages), the §101 nuance (the synthetic aptamer is clearly eligible — a plus — but diagnostic correlations face Mayo; claim the aptamer + technical assay), the composition-vs-platform split (specific aptamers vs the SELEX/proteomics platform), the modification importance (modified aptamers — SOMAmers — expanded what's bindable and robust), the data/proteomics moat (large proteomic datasets), the validation/adoption reality, and a landscape where SELEX improvements, aptamer compositions, modifications, diagnostics, and proteomics are the durable assets; understand that SELEX basics are public, so the durable IP is in SELEX improvements, specific (modified) aptamer compositions, biosensor/diagnostic methods, proteomics platforms, and §101-robust claiming — with specific aptamers, modifications, and the proteomics platform/data often the real moat, and that affinity/specificity, advantages over antibodies, validation, and §101-robust claims matter as much as patents; identify whitespace in modified aptamers, diagnostics, and proteomics. APTAMER STARTUP IP STRATEGY: SELEX IMPROVEMENTS, SPECIFIC (MODIFIED) APTAMER COMPOSITIONS, BIOSENSOR/DIAGNOSTIC METHODS, PROTEOMICS PLATFORMS, AND §101-ROBUST CLAIMING ARE THE IP: patent SELEX improvements, specific/modified aptamer compositions, biosensor/diagnostic methods, proteomics platforms, and engineered-aptamer + technical-assay claims; THE SYNTHETIC APTAMER IS CLEARLY PATENT-ELIGIBLE (A §101 PLUS) — BUT DIAGNOSTIC CORRELATIONS FACE MAYO: the engineered aptamer is a man-made molecule (clearly eligible composition, unlike natural biomolecules) — but if you claim 'detect protein X correlates with disease Y' it risks Mayo; claim the APTAMER + the concrete technical ASSAY/method; SPECIFIC (MODIFIED) APTAMERS ARE THE CORE COMPOSITION IP: the specific aptamer-target pair (and chemical modifications — SOMAmers — improving affinity/stability/proteome coverage) is the durable asset; SELEX IMPROVEMENTS ARE THE WHITESPACE (BASICS ARE PUBLIC): foundational SELEX is older/public — faster/higher-affinity/automated/difficult-target/cell-SELEX improvements are patentable engine IP; PROTEOMICS PLATFORM + DATA IS A MOAT (SOMALOGIC MODEL): large-scale multiplexed aptamer proteomics (thousands of proteins) and the resulting datasets are a distinctive platform/moat; MUST BEAT ANTIBODIES ON SPECIFIC ADVANTAGES: aptamers compete with entrenched antibodies — win on cost/stability/reproducibility/no-animals/difficult-targets, not as a like-for-like antibody replacement; BIOSENSOR/DIAGNOSTIC INTEGRATION LEVERAGES APTAMER ADVANTAGES: aptamers' chemical attachability/stability make them easy to integrate into sensors/tests — application IP; MODIFICATIONS/AFFINITY/VALIDATION MATTER AS MUCH AS PATENTS: affinity/specificity, advantages over antibodies, validation, and enforceable claims drive value; WHEN TO PATENT: NOVEL SELEX/APTAMER/DIAGNOSTIC/PROTEOMICS WITH MEASURED DATA + ELIGIBLE CLAIMS: file once a method shows measured results (aptamer affinity/specificity + stability/nuclease resistance + assay sensitivity/specificity + proteome coverage/multiplexing) AND can be claimed (engineered aptamer + technical assay) — measured aptamer affinity/specificity/stability, assay performance, and proteome coverage are the critical aptamer IP metrics; KEY FTO CHECKLIST: SomaLogic (SomaScan/SOMAmers/modified aptamers); Aptamer Group/Base Pair; academic SELEX (foundational, older/public); SELEX/aptamer selection (cell-SELEX/automated/difficult-target improvements); aptamer composition (specific sequence/target); chemical modification (nuclease resistance/affinity/SOMAmer/half-life); biosensor/diagnostic (aptasensor/lateral-flow/electrochemical/beacon); proteomics/multiplexed measurement (panel/readout/normalization); §101 (engineered aptamer + assay vs natural correlation, Mayo); aptamer therapeutics; proteomic data (moat).